← All trials
NCT04598919
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 12, 2020
- Primary completion
- Sep 28, 2022
- Completion date
- Dec 31, 2022
- First posted
- Oct 22, 2020
- Last posted
- Dec 31, 2020
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of Colorado, DenverLead sponsor
- AstraZenecaCollaborator
- Yale UniversityCollaborator
- Yale UniversityOverall official - principal investigator
- University of Colorado, DenverOverall official - principal investigator
- Icahn School of Medicine at Mount SinaiCollaborator
- Icahn School of Medicine at Mount SinaiOverall official - principal investigator
- National Center for Advancing Translational Science (NCATS)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.